COMMUNIQUÉS West-GlobeNewswire

AnswersNow Launches Corporate Advisory Board to Advance Scale of Innovative Virtual Autism Platform
22/07/2025
Board brings together diverse industry veterans representing insurers, educators, clinicians and healthcare providers to ensure a robust, practical approach to closing the autism support gap in America RICHMOND, Va., [...]
Sutro Biopharma Announces Research Collaboration with the FDA to Advance Regulatory Standards for Antibody Drug Conjugates
22/07/2025
SOUTH SAN FRANCISCO, Calif., July 22, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), an oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), [...]
aTyr Pharma Announces Last Patient Visit in Phase 3 EFZO-FIT™ Study of Efzofitimod in Patients with Pulmonary Sarcoidosis
22/07/2025
Topline results expected in the third quarter of 2025. SAN DIEGO, July 22, 2025 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the [...]
Health care advocates afraid of major cuts and privatization hold rally at Council of the Federation
22/07/2025
HUNTSVILLE, Ontario, July 22, 2025 (GLOBE NEWSWIRE) -- Outside the Council of the Federation and the gathering of First Ministers, public health care advocates from across Canada will be joining a rally and car [...]
Pacira BioSciences Announces Strategic Collaboration to Significantly Expand ZILRETTA Promotional Efforts
22/07/2025
Partnership expected to advance 5x30 strategy by increasing ZILRETTA sales calls and extensively expanding patient access BRISBANE, CA, July 22, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), the [...]
Daxor’s Blood Volume Analysis Technology Accelerates Market Penetration with Three New Facility Adoptions
22/07/2025
Continued Integration of Daxor’s ezBVA Lab Service and On-Site Analyzers Fuels Positive Outlook Oak Ridge, TN, July 22, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume [...]
Hydreight to Participate in the Canaccord Genuity 45th Annual Growth Conference in Boston
22/07/2025
VANCOUVER, British Columbia, July 22, 2025 (GLOBE NEWSWIRE) -- Hydreight Technologies Inc. (TSXV: NURS | OTCQB: HYDTF | FSE: SO6) (“Hydreight” or the “Company”), a telehealth and mobile medical company operating across [...]
Survivor Healthcare Announces the Appointment of Catherine Cowan as Senior Vice President of Clinical Operations
22/07/2025
Cowan will oversee clinical strategy, quality improvement, and expansion of multidisciplinary care teams Appointment strengthens Survivor Healthcare’s mission to deliver integrated, high-quality primary care to cancer [...]
NewAmsterdam Pharma to Present Alzheimer’s Biomarker Data from BROADWAY Trial at AAIC 2025
22/07/2025
– NewAmsterdam to host conference call at 10:00 a.m. ET on Wednesday, July 30th – NAARDEN, the Netherlands and MIAMI, July 22, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or [...]
SciSparc Ltd. Regains Compliance with Nasdaq Minimum Bid Price Notification
22/07/2025
Tel Aviv, July 22, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (“SciSparc” or the “Company”) (Nasdaq: SPRC), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and [...]
Beyond Air Awarded Therapeutic Gases Agreement with Premier, Inc.
22/07/2025
GARDEN CITY, N.Y., July 22, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of [...]
Reunion Neuroscience Announces Publication of RE104 Phase 1 Data in The Journal of Clinical Psychopharmacology
22/07/2025
-- Phase 1 Data Highlight RE104 Favorable Safety Profile and Short Duration Psychoactive Experience -- -- Topline Results from RECONNECT Phase 2 Trial of RE104 in Postpartum Depression (PPD) Anticipated in Q3 2025 -- [...]
Rezolute to Participate in the BTIG Virtual Biotechnology Conference
22/07/2025
REDWOOD CITY, Calif., July 22, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused by hyperinsulinism, today [...]
BridgeBio to Host Second Quarter 2025 Financial Results Conference Call on Tuesday, August 5, 2025 at 4:30 pm ET
22/07/2025
PALO ALTO, Calif., July 22, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced that it [...]
Arch Biopartners Announces Start of Patient Recruitment in Phase II PONTIAK Trial Targeting Drug-Toxin-Related Acute Kidney Injury (AKI)
22/07/2025
TORONTO, July 22, 2025 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today that the investigator-led Phase II trial titled “ P revention O f N ephro T [...]
Telix Reports $204M Revenue, Up 63% YOY
22/07/2025
MELBOURNE, Australia and INDIANAPOLIS, July 22, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today provides an update on its commercial and operational performance for the [...]
Llusern Scientific Announces Key Appointments to Strengthen its Executive Team
22/07/2025
CTO, CMO and CFO appointments to advance the commercial launch of its precision point-of-care diagnostic Lodestar DX for UTIs worldwide CARDIFF, United Kingdom, July 22, 2025 (GLOBE NEWSWIRE) -- Llusern Scientific, a [...]
Bavarian Nordic Receives Acceptance from Health Canada for Review of the New Drug Submission for its Chikungunya Vaccine
22/07/2025
COPENHAGEN, Denmark, July 22, 2025 – Bavarian Nordic A/S (OMX: BAVA) announced today that Health Canada has accepted for review the Company’s application for licensure of the single-dose, virus-like particle (VLP) [...]
Scancell reports Phase 2 data showing strongly improved outcomes in Late-Stage Melanoma with its Immunobody® iSCIB1+
22/07/2025
SCOPE trial of SCIB1/iSCIB1+ plus standard of care shows excellent results encompassing efficacy, durability, immune responses and safety Overall response rate for iSCIB1+ was 69% for target HLA type patients, [...]

Pages